论文部分内容阅读
背景:川芎嗪与噻氯匹定可用于预防高危脑卒中患者的发病及中、重度脑卒中存活者再发病或并发心肌梗死,虽然川芎嗪的副反应低于噻氯匹定,但两者疗效如何还需要从多方面进行评价。目的:比较川芎嗪与噻氯匹定对缺血性脑卒中患者血小板聚集性影响,为预防脑卒中复发用药提供客观依据。设计:随机对照的研究。单位:武汉大学人民医院神经内科。对象:2001-02/2002-05武汉大学人民医院收治的112例确诊为缺血性脑卒中患者,筛选出56例符合以上标准者随机分为治疗1组(静滴川芎嗪)和治疗2组(静滴噻氯匹定)各28例。方法:体外试验:取患者空腹静脉血,用比浊法测定血小板聚集曲线。临床试验:治疗1组用川芎嗪300mg/d静滴;治疗2组用噻氯匹定250mg/d静滴。疗程均为1个月,疗程结束后测定血小板聚集曲线。主要观察指标:①药物对缺血性脑卒中患者血小板聚集抑制率的影响。②两组患者治疗前后血小板最大聚集率的变化。结果:噻氯匹定与川芎嗪均有较强的抑制血小板的聚集反应,噻氯匹定略强于川芎嗪,但两者比较,差异无显著性意义(P>0.05)。治疗1组和治疗2组治疗前后血小板最大聚集率分别为(58.6±10.7),(37.8±12.2)%,(60.2±10.9),(34.6±13.6)%,两组与治疗前相比较,差异有显著性意义(t=6.78,7.77,P<0.01)。结论:无论是体外实验还是
BACKGROUND: Tetramethylpyrazine and ticlopidine can be used to prevent the onset of high-risk stroke and the recurrence of myocardial infarction in moderate or severe stroke patients. Although the side effect of tetramethylpyrazine is lower than ticlopidine, the efficacy of both How to evaluate from many aspects. Objective: To compare the effects of ligustrazine and ticlopidine on platelet aggregation in patients with ischemic stroke and provide an objective basis for prevention of recurrent stroke. Design: A Randomized Controlled Study. Unit: Department of Neurology, Wuhan University People’s Hospital. PARTICIPANTS: One hundred and twelve patients diagnosed as ischemic stroke admitted to Wuhan University People’s Hospital from February 2001 to May 2002 were screened out and 56 patients who met the above criteria were randomly divided into treatment group 1 (intravenous infusion ligustrazine) and treatment group 2 (Intravenous ticlopidine) 28 cases each. Methods: In vitro test: Take fasting venous blood of patients and measure platelet aggregation curve by turbidimetry. Clinical trials: 1 group treated with ligustrazine 300mg / d intravenous infusion; treatment 2 groups with ticlopidine 250mg / d intravenous infusion. Course of treatment were 1 month after the end of treatment measured platelet aggregation curve. MAIN OUTCOME MEASURES: ① The influence of drugs on platelet aggregation inhibition rate in patients with ischemic stroke. ② The changes of the maximum aggregation rate of platelets in both groups before and after treatment. Results: Both ticlopidine and ligustrazine inhibited platelet aggregation strongly. Ticlopidine was slightly stronger than ligustrazine, but there was no significant difference between them (P> 0.05). The maximum aggregation rate of platelet before and after treatment in treatment group 1 and treatment group 2 were (58.6 ± 10.7), (37.8 ± 12.2)%, (60.2 ± 10.9) and (34.6 ± 13.6)%, respectively There was significant (t = 6.78, 7.77, P <0.01). Conclusion: Whether it is an in vitro experiment or not